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Purpose of the study: Oncogeriatric patients often present with significant co-morbidities 
and associated polypharmacy, consequently leading to an increased risk of adverse drug-
drug interactions (DDIs) possibly interfering with cancer therapy. Medication review is an 
essential part of a Comprehensive Geriatric Assessment (CGA), the key treatment approach 
in elderly cancer patients. Our objective was to describe medication use in this population 
and evaluate the use of Lexicomp® interaction analyser, an online drug information database 
(available through “uptodate”)2, within CGA for adequate identification of potentially harmful 
DDIs. 
Methods: We retrospectively reviewed data of 149 elderly cancer patients that presented at 
the General Hospital Groeninge or Ghent University Hospital between January 2010 and 
February 2012 for their cancer treatment. Sixty-three percent participated in an observational 
study recruiting head and neck cancer patients (H&N-group)3, 37% in a registry recruiting 
general oncology patients (GO-group). Drug information was collected once before therapy 
decision or at therapy start, by a health professional, through the medical interview within 
CGA. Drug class usage was quantified and potential DDIs were assessed and categorized 
(risk rating “C”: monitor therapy, “D”: consider therapy modification, “X”: avoid combination) 
with Lexicomp®. 
Results: The population under study comprised mainly male patients (72%), aged 74 (range 
65 – 90 years), with primary tumours of the following origins: head and neck (65.8%), 
urological (10.1%), gynaecological (8.7%), gastro-intestinal (6.0%), breast (4.7%), skin 
(2.0%), hematological (1.3%) and occult primary (1.3%). On average, H&N and GO-patients 
took 5 and 8 prescription drugs at presentation, respectively. An average of 4 drugs were 
added in both groups as part of their proposed therapy. Potential DDIs (n=211 H&N; n=247 
GO) were detected by Lexicomp® in 64.9% (85.3% “C”, 14.7% “D”, 0% “X”) and 83.6% 
(83.4% “C”, 15.8% “D”, 0.8% “X”) of all H&N and GO patients, respectively, at therapy start. 
Administration of cancer-therapy-related drugs lead to additional DDIs (n=75 H&N; n=68 GO) 
in 73.7% (90.7% “C”, 9.3% “D”, 0% “X”) and 58.3% (72.1% “C”, 26.5% “D”, 1.5% “X”) of H&N 
and GO cases that were scheduled for systemic cancer therapy (38/94 H&N, 36/55 GO) 
respectively. DDIs occurred mainly with supportive drugs (100% H&N and 83.8% GO). 
Sixteen percent of potential DDIs were identified with anti-neoplastic drugs in the GO-group.  
In 28.7% and 60.0% of H&N and GO patients, respectively, at least one drug was not 
recognized by Lexicomp®. 
Conclusions: Use of Lexi Comp® online drug database for medication review within CGA is 
feasible. It could reduce the administration of inappropriate drugs and/or enhance patient 
monitoring by increasing physician awareness for potentially severe drug interactions, and in 
that way improve the quality of patient-individualised therapy. 
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 Table 1: Medication use and drug-drug interactions of elderly cancer patients 
Chronic prescription drug characteristics of all patients 
under study 
H&N Group 
(n=94) 
GO-group 
(n=55) 
 
Chronic prescription drugs 
Average [n] 
Range 
 
 
 
5 
0-15 
 
 
8 
1-19 
 
Total number of DDIs [% (n)] 
Risk rating “C” 
Risk rating “D” 
Risk rating “X” 
 
Number of patients exposed to potential DDIs [% (n)] 
 
 
100.0 (211) 
85.3 (180) 
14.7 (31) 
0 (0) 
 
64.9 (61) 
 
100.0 (247) 
83.4 (206) 
15.8 (39) 
0.8 (2) 
 
83.6 (46) 
Cancer drug characteristics of a subset of patients 
scheduled for (systemic) cancer therapy (with curative, 
palliative or symptomatic intent) 
H&N subgroup 
(n=38) 
GO subgroup 
(n=36) 
 
Anti-neoplastic and cancer supportive drugs 
Average [n] 
Range 
 
 
 
4 
-** 
 
 
 
4 
1-12 
 
 
Total number of additional DDIs [% (n)] 
Risk rating “C” 
Risk rating “D” 
Risk rating “X” 
With supportive drugs 
Total number of interactions [% (n)] 
With anti-neoplastic drugs 
Total number of interactions [% (n)] 
 
Number of patients exposed to potential DDIs [% (n)] 
 
 
100.0 (75) 
90.7 (68) 
9.3 (7) 
0 (0) 
 
100.0 (75) 
 
0 (0) 
 
73.7 (28) 
 
 
100.0 (68) 
72.1 (49) 
26.5 (18) 
1.5 (1) 
 
83.8 (57) 
 
16.2 (11) 
 
58.3 (21) 
 
**Four drugs (one anti-neoplastic drug and three additional supportive drugs) were per chemo(bio)therapy 
regimen included in the interaction analysis of H&N cancer patients; DDI: drug-drug interaction; risk rating “C”: 
monitor therapy; risk rating “D”: consider therapy modification; risk rating “X”: avoid combination 
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